Reduced Bone Mineral Density in Patients with Schizophrenia Receiving Prolactin Raising Anti-Psychotic Medication

Patients with schizophrenia frequently develop drug-induced hyperprolactinaemia and consequent hypogonadism. Reduced bone mineral density as a consequence of hyperprolactinaemia-induced hypogonadism has been well documented in medical, but not psychiatric, disorders. Little attention has been given...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychopharmacology (Oxford) 2003-12, Vol.17 (4), p.455-458
Main Authors: Meaney, Anna Maria, O’Keane, Veronica
Format: Article
Language:English
Subjects:
Adult
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Biological and medical sciences
Bone Density - drug effects
Bones
Drug therapy
Drug toxicity and drugs side effects treatment
Female
Humans
Hyperprolactinemia - chemically induced
Hypogonadism - chemically induced
Male
Medical sciences
Minerals
Osteoporosis
Osteoporosis - chemically induced
Pharmacology. Drug treatments
Prolactin - blood
Risperidone - adverse effects
Risperidone - therapeutic use
Schizophrenia
Schizophrenia - drug therapy
Side effects
Toxicity: osteoarticular system
Toxicity: urogenital system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with schizophrenia frequently develop drug-induced hyperprolactinaemia and consequent hypogonadism. Reduced bone mineral density as a consequence of hyperprolactinaemia-induced hypogonadism has been well documented in medical, but not psychiatric, disorders. Little attention has been given to the potential risk of developing osteoporosis secondary to anti-psychotic-induced hyperprolactinaemia. Three cases are presented that illustrate how this debilitating but silent disease may affect even those young individuals with schizophrenia.
ISSN:0269-8811
1461-7285
DOI:10.1177/0269881103174011